|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1993-1-7
|
|
pubmed:abstractText |
This phase II study was undertaken to assess the efficacy and toxicity of alternating administration of pentostatin (deoxycoformycin [DCF]) and interferon alfa-2a (IFN) in patients with advanced or refractory mycosis fungoides (MF) or the Sézary syndrome (SS).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1907-13
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1453206-Adult,
pubmed-meshheading:1453206-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1453206-Female,
pubmed-meshheading:1453206-Humans,
pubmed-meshheading:1453206-Interferon-alpha,
pubmed-meshheading:1453206-Male,
pubmed-meshheading:1453206-Middle Aged,
pubmed-meshheading:1453206-Mycosis Fungoides,
pubmed-meshheading:1453206-Neoplasm Staging,
pubmed-meshheading:1453206-Pentostatin,
pubmed-meshheading:1453206-Recombinant Proteins,
pubmed-meshheading:1453206-Sezary Syndrome,
pubmed-meshheading:1453206-Skin Neoplasms,
pubmed-meshheading:1453206-Survival Analysis,
pubmed-meshheading:1453206-Treatment Outcome
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
|
|
pubmed:affiliation |
National Cancer Institute, National Institutes of Health, Bethesda, MD.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
